Bayesian benefit-risk dose optimisation of BAL0891, a first-in-class TTK/PLK1 inhibitor, plus paclitaxel: recommended phase 2 dose selection in metastatic urothelial carcinoma (TTK-CS-101) (EORTC-NCI-AACR 2026) - Sep 11, 2026 - Abstract #337; PB-129; Pres time: Nov 20, 2026; Location: Exhibition Hall; "Abstract will be available as of 4 November (with consent of the author)"
Metastases • P2 data • Oncology • Solid Tumor • Urothelial Cancer
|